WaveMan
WaveMan · Company
MIRM · Mirum Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MIRM Mirum Pharmaceuticals (MIRM) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001759425
Quote by TradingView
Form 144 · 7
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
190
13F, latest reported quarter
Conversions, 180 days
16
Codes C/M, not in net · $1.5M priced

What the filings say about MIRM

Insiders, 180 days
-$18.4M net sold
4 sellers · 10% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$10.8M
7 notices

Mirum Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Mirum Pharmaceuticals, Inc. insiders sold a net $18.4M of stock across 167 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
BJERKHOLT ERIC
CHIEF FINANCIAL OFFICER
SELL
2026-09-15 SECtraded 2026-09-14
9,943
$978.1K
-14.5%
Context
  • 15 earlier Form 4 trades (code P or S) here by this insider (3 buys, 12 sales), the last on Aug 11, 2026.
  • +27.0% median (+21.7% mean) 90-day return after 3 previous buys.
  • The trade is 22.2% of the 44,745 shares held after it.
  • 2 other insiders sold within 30 days.
  • 190 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF FINANCIAL OFFICER BJERKHOLT ERIC sold about $978.1K of MIRM on Sep 14, 2026; 2 other insiders sold within 30 days and 190 funds added in the latest 13F quarter.
Howe Jolanda
SVP, GLOBAL CONTROLLER
SELL
2026-09-03 SECtraded 2026-09-02
658
$65.8K
-17.5%
Context
  • 26 earlier Form 4 trades (code P or S) here by this insider (26 sales), the last on Aug 18, 2026.
  • The trade is 106.8% of the 616 shares held after it.
  • 2 other insiders sold within 30 days.
  • 190 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, GLOBAL CONTROLLER Howe Jolanda sold about $65.8K of MIRM under a 10b5-1 plan on Sep 2, 2026; 2 other insiders sold within 30 days and 190 funds added in the latest 13F quarter.
Peetz Christopher
CHIEF EXECUTIVE OFFICER
SELL
2026-09-03 SECtraded 2026-09-01
8,312
$815.2K
-17.5%
Context
  • 31 earlier Form 4 trades (code P or S) here by this insider (1 buy, 30 sales), the last on Aug 10, 2026.
  • The trade is 3.8% of the 216,128 shares held after it.
  • 2 other insiders sold within 30 days.
  • 190 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER Peetz Christopher sold about $815.2K of MIRM under a 10b5-1 plan on Sep 1, 2026; 2 other insiders sold within 30 days and 190 funds added in the latest 13F quarter.
Peetz Christopher
CHIEF EXECUTIVE OFFICER
SELL
2026-09-03 SECtraded 2026-09-01
21,688
$2.1M
-17.5%
Context
  • 31 earlier Form 4 trades (code P or S) here by this insider (1 buy, 30 sales), the last on Aug 10, 2026.
  • The trade is 11.2% of the 194,440 shares held after it.
  • 2 other insiders sold within 30 days.
  • 190 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF EXECUTIVE OFFICER Peetz Christopher sold about $2.1M of MIRM under a 10b5-1 plan on Sep 1, 2026; 2 other insiders sold within 30 days and 190 funds added in the latest 13F quarter.
Howe Jolanda
SVP, GLOBAL CONTROLLER
SELL
2026-08-19 SECtraded 2026-08-18
40,000
$4.0M
-14.2%
Context
  • 25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Aug 3, 2026.
  • The trade is 3139.7% of the 1,274 shares held after it.
  • 2 other insiders sold within 30 days.
  • 190 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, GLOBAL CONTROLLER Howe Jolanda sold about $4.0M of MIRM on Aug 18, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 190 funds added in the latest 13F quarter.
167 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 162 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$18.4M over 180 days
-$10.8M over 90 days
below 88% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
190 funds bought in last quarter
more than 89% of Pharma & Biotech
Revenue
+54.7% year over year
more than 78% of Pharma & Biotech
Margin
-4.5% net margin
more than 70% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
11.8% of the float short (float per yahoo 2026-10-27) · 7.3 days to cover · settled 2026-10-15
more than 73% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MIRM

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+20.0%12M
-8%+23%+54%+85%2025-102025-122026-022026-042026-062026-082026-10 2026-01-23 · Heron Patrick J bought $9.0M2026-08-18 · Howe Jolanda sold $4.0M2025-12-19 · GREY MICHAEL G sold $3.9M2026-03-16 · Peetz Christopher sold $3.8M2025-12-01 · GREY MICHAEL G sold $3.7M2025-11-21 · GREY MICHAEL G sold $3.5M2026-09-01 · Peetz Christopher sold $2.1M2026-06-01 · Peetz Christopher sold $1.6M2026-03-16 · Radovich Peter sold $1.5M2026-07-06 · Peetz Christopher sold $1.5M2026-08-10 · Peetz Christopher sold $1.2M2026-09-14 · BJERKHOLT ERIC sold $978.1K2026-02-02 · Peetz Christopher sold $940.9K2026-09-01 · Peetz Christopher sold $815.2K2026-03-16 · BJERKHOLT ERIC sold $670.3K2026-03-16 · Quan Joanne sold $670.3K2026-06-01 · Peetz Christopher sold $665.9K2026-01-22 · Peetz Christopher sold $662.5K2026-01-26 · Peetz Christopher sold $657.1K2026-01-20 · Quan Joanne sold $623.9K2026-08-11 · BJERKHOLT ERIC sold $599.5K2026-08-10 · Peetz Christopher sold $597.2K2026-07-06 · Peetz Christopher sold $511.5K2026-03-16 · Howe Jolanda sold $435.2K2025-12-22 · Ramasastry Saira sold $400.0K2026-06-01 · Ramasastry Saira sold $397.7K2026-07-06 · BJERKHOLT ERIC sold $380.1K2026-07-01 · Howe Jolanda sold $326.5K2026-01-26 · Radovich Peter sold $302.3K2026-02-02 · Radovich Peter sold $271.8K2026-06-17 · Howe Jolanda sold $264.5K2026-06-01 · Peetz Christopher sold $246.3K2026-07-06 · Peetz Christopher sold $244.4K2026-08-10 · Peetz Christopher sold $230.3K2026-01-22 · Radovich Peter sold $222.3K2026-05-15 · Ramasastry Saira sold $218.9K2026-07-06 · Peetz Christopher sold $213.4K2026-06-08 · BJERKHOLT ERIC sold $209.6K2026-02-13 · Ramasastry Saira sold $204.2K2026-04-15 · Ramasastry Saira sold $193.8K2026-08-03 · Howe Jolanda sold $193.7K2026-06-01 · Peetz Christopher sold $192.5K2026-09-15 · ERIC BJERKHOLT filed to sell $978.1K2026-09-02 · JOLANDA MARIE HOWE filed to sell $65.8K2026-09-01 · CHRISTOPHER PEETZ filed to sell $3.0M2026-08-18 · JOLANDA MARIE HOWE filed to sell $4.0M2026-08-11 · ERIC BJERKHOLT filed to sell $599.5K2026-08-10 · CHRISTOPHER PEETZ filed to sell $2.0M2026-08-03 · JOLANDA MARIE HOWE filed to sell $193.7K2026-07-06 · ERIC BJERKHOLT filed to sell $611.3K2026-07-06 · CHRISTOPHER PEETZ filed to sell $2.4M2026-07-01 · JOLANDA MARIE HOWE filed to sell $326.5K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MIRM: institutional holders (13F)

13F holdings, latest reported quarter
Frazier Life Sciences Management, L.P.
7,679,684 sh
$899.1M
Jupiter Topco LLC
5,909,184 sh
$691.7M
BlackRock, Inc.
4,390,063 sh
$513.9M
FMR LLC
3,670,314 sh
$429.7M
VANGUARD PORTFOLIO MANAGEMENT LLC
2,377,019 sh
$278.3M

Congress trades in MIRM

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MIRM planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
ERIC BJERKHOLT
Filed 2026-09-15
$978.1K
JOLANDA MARIE HOWE
Filed 2026-09-02
$65.8K
CHRISTOPHER PEETZ
Filed 2026-09-01
$3.0M
JOLANDA MARIE HOWE
Filed 2026-08-18
$4.0M
ERIC BJERKHOLT
Filed 2026-08-11
$599.5K

MIRM mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
F/m Emerald Life Sciences Innovation ETF
$5.2M position · as of 2026-05-31
4.9%
ALPS Medical Breakthroughs ETF
$6.3M position · as of 2026-05-31
3.9%
Eventide Healthcare & Life Sciences Fund
$62.1M position · as of 2026-06-30
3.5%
RiverPark/Next Century Growth Fund
$335.4K position · as of 2026-06-30
2.8%
Eventide Gilead Fund
$83.0M position · as of 2026-06-30
2.4%
Nomura Small Cap Growth Fund
$27.5M position · as of 2026-06-30
2.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
24 registered trials, 12 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
9
Phase 2
4 active
9
Phase 3
3 active
1
Phase 4
1 active
2
Not applicable
2 active
2
Multi-phase
2 active
What changed recently
A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM
2026-10-08 · Completion moved 2026-07 → 2026-07-08
Phase 1
A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM
2026-10-08 · Recruiting → Completed
Phase 1
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return · Christopher Peetz
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$10.4M
$29.7M
$3.5M
+395%
+25%
2024
$6.6M
$13.0M
$3.0M
+159%
-7%
2023
$6.5M
$9.4M
$3.4M
+85%
-6%
2022
$4.4M
$6.5M
$1.5M
+22%
-10%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $18.4M sold by insiders over 180 days, 190 funds added last quarter, $10.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MIRM financials

Revenue growth
+54.7%
XBRL, annual
Net margin
-4.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$618.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-139.2%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$228.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-703.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-97.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-118.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-4.2%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$521.3M$336.9M$186.4M$77.1M
Operating income-$22.1M-$87.6M-$109.2M-$131.2M
Net income-$23.4M-$87.9M-$163.4M-$135.7M
EPS (diluted)-0.47-1.85-4.00-4.02
Operating cash flow$55.8M$10.3M-$70.9M-$120.1M
Cash$296.7M$222.5M$286.3M$28.0M
SEC XBRL, fiscal years, as known on 2026-10-28

MIRM Stock Sonar score 5/7 axes

Find similar shapesCompare

MIRM ranks highest on institutional and government (89th percentile) and growth (78th), and lowest on insider conviction (6th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
17
Inputs
  • Return on equity-703.0% · 6 pct, sector of 545
  • Return on assets-97.2% · 25 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-118.9% · 21 pct, sector of 576
Growth
78
Inputs
  • Revenue growth, YoY+54.7% · 78 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
6
Inputs
  • Net Form 4 buying (codes P and S), 180d-$15.4M · 12 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
89
Inputs
  • Funds adding, latest quarter190 · 89 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
37
Inputs
  • Short interest, % of float+11.8% · 34 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+12.7% · 40 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MIRM filings, in plain words

Are Mirum Pharmaceuticals insiders buying or selling MIRM?

In the 180 days to 2026-10-28, Mirum Pharmaceuticals insiders were net sellers, a net $18.4M across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of MIRM?

Yes. 7 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $10.8M of stock; the latest, by ERIC BJERKHOLT, was filed 2026-09-15.

Read the full summary

In the 180 days to 2026-10-28, Mirum Pharmaceuticals insiders were net sellers of MIRM, a net $18.4M across purchases and sales reported on Form 4 by 4 sellers. 10% of the 31 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 7 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $10.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies